CHICAGO, October 15, 2024--(BUSINESS WIRE)--MAIA Biotechnology ... related to the company’s second generation of proprietary telomere-targeting THIO prodrugs has been accepted for poster ...

About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq ... today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of ...

Session: Oral Poster Presentation – Guided Poster TourSession ... the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD ...

The clinical trial is sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103. About IOB-032/PN-E40 Phase 2 Basket Trial in ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

If anyone has information on the whereabouts of the TAK-279 poster, Fierce Biotech is standing by to collect tips. We intend to work tirelessly—at least until the next news cycle, anyway—to ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Times: Poster hall ...